LPA and atherosclerosis: As prespecified in the protocol, this phase 1 trial (NCT04606602) subsequently followed up with 13 out of the 32 healthy participants for an extended period of time (i.e., 365 days), as well as an additional 36 enrolled adult patients with ASCVD and baseline Lp(a) levels ≥150 nmol/L (60 mg/dL) that received two doses of a placebo, 200 mg of zerlasiran at a 4-week interval, or 300 mg or 450 mg at an 8-week interval [53].